Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Everything is falling into place for Elite. Being on track to self-sufficiency would allow Elite to finance R & D of its ELI product line. A win-win for the company and shareholders.
Cheers!
Elite Pharmaceuticals, Inc. Reports Strong Growth for Second Quarter of Fiscal Year 2016
Webcast and Conference Call Scheduled for Tuesday, November 10th at 11:00 AM EST
Elite Pharmaceuticals, Inc.
5 minutes ago
GlobeNewswire
Cheers!
NORTHVALE, N.J., Nov. 09, 2015 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (ELTP), announced results for the quarter ended September 30, 2015, the second quarter of its 2016 fiscal year.
Consolidated revenues for the second quarter of Fiscal 2016 were $2.7 million, a 115% increase on a year-on-year basis. The increase in revenues is due to the continued growth of Elite’s niche generic product lines. During the quarter, Elite invested an additional $4.2 million in the development of ELI-200, the first product in Elite’s line of abuse-deterrent opioids.
In October, Elite announced positive top-line results from the Phase 3 pivotal trial of its lead abuse-deterrent opioid, ELI-200, for the treatment of moderate to severe pain. The Company is on schedule to file a New Drug Application with the U.S. Food and Drug Administration later this year. Elite will provide an update of development activities during the conference call.
“Another outstanding quarter. Our generic products set another revenue record, and we successfully completed Phase 3 trials for ELI-200,” commented Nasrat Hakim, President and CEO of Elite. “Elite has never been stronger as we steadily move towards the filing of ELI-200 this year, the expected launch next year and the continued development of a range of abuse deterrent opioids.”
Be on the lookout for a breakout. Conditions look right.
Cheers!
That is indeed a good sign as we await the perfect storm.
Cheers!
ELTP is a lock. We will see the critics drop out through attrition. Expecting "killer" revenues and future ELI homers.
Cheers!
Here comes the POWER CHEERS!
Cheers!
Yup, that is how I see it, too.
Cheers!
I agree. Some folks are ahead of themselves and calling $38-PPS. Keep it real with the $1-$2 target and after NDA/FDA-approval for our ELI drugs, then we could discuss it. Elite has a long way to go and she needs to prove investors her worth. Do not get me wrong; Aqua is a long-term, value investor.
Cheers!
Unfortunately, yes.
Cheers!
Looks like a four steps drop to move the PPS forward and a touchdown to NDA/ELI-200. Cheers!
Yes sir, we have some folks on this board that want to influence the PPS. Let's keep it real and discuss what makes ELTP undervalued.
Cheers!
All bets are on NDA. Looking forward to an entertaining CC that would rock our world and knock our socks off.
Cheers!
Steady up she goes. Cheers!
Just to clarify, Aqua is already deep with ELTP shares. Let's be realistic and defer any opinions about the PPS hitting $38-PPS per Lasers. This would give new investors the wrong impression about ELTP and would only prove that Dr. L is correct (P and D).
Cheers!
Once I see ELTP hit $4-$5 pps, I am on board.
Cheers!
WOW, $38 pps is a BOLD statement! If we do without a RS, then that would make a majority of investors retired and wealthy. But that would take some time. For now, $2-$5 is realistic.
Cheers!
Should be a drama-filled, exciting week. Investors' nerves will be tested especially for new investors. There will be the expected profit-taking by retail traders. Hopefully, MMs and professional investors could buy during a sell-off to calm investors' nerves. But all depends on guidance of the CC and financials.
Cheers!
Yup, that is what you've implied about Elite.
Cheers!
No sir, actual pump-and-dumps are scams. But there are instances in which investors create a pump-and-dump opportunity. Allow me to use Apple Inc. as an example. We all know the PPS is pumped before earnings and then dumped right after. Does that make Apple, Inc. a bad company for shareholders to profit in the end?
Cheers!
Makes sense. I do not think retail investors are mostly responsible for the spike in the previous day's' volume when their participation is at an all time historic low. Professional investors with deeper pockets are here to stake their claim, and test ELTP's performance. It will be fun, indeed.
Cheers!
The only thing that I hear from Elite are more PROFITS and DRUGS. Highly unlikely to be a scam when conducting such an operation requires substantial financial resources and sophisticated planning that would be next to impossible to be carried out.
Also, Elite is building the fundamentals and promoting growth in its diversified drug pipeline to facilitate its goal of uplisting its stock. Not your typical OTC company that would be a great pump-and-dump candidate.
Cheers!
Remembered when Aqua owned shares of General Growth Properties(GGP) after they declared the Ala Moana Shopping Center bankruptcy. I did not hesitated to accumulate bargain shares, and made a killing a few months afterwards. Bill Ackerman owned GGP shares, too. I see ELTP at bargain prices, too. Investors here will make a handsome profit.
Cheers!
Who let the dogs out? Elite is off to the races.
Cheers!
This applies to all stocks.
Cheers!
Their drug pipeline is limited. Elite has a net income profit and a diversified drug pipeline that is seeing growth. Also, Elite is easy to pronounce and remember.
Cheers!
It appears the stakes are getting high and investors want to be in the game before the fun begins.
Cheers!
Subliminally, just more PROFITS and DRUGS for sale by Elite Pharma. The pump-and-dump days are in the past.
Cheers!
Here comes the after lunch crowd for you, east coast investors. The setup for next week is taking shape.
Cheers!
You offered the board only opinions and NO substantial facts to support any of your assertions on Elite and its technologies. We could all expect guidance for 2016 in the upcoming CC.
Cheers!
No scientific publications exists on Elite's science and technology since they are patents and proprietary information that is under lock-and-key in their vault. Filing an NDA for ELI-200 and FDA-approval is all investors need.
Cheers!
LOL, LOL! The only problem with that "pump and dump" assertion is that you have overlooked the progress Elite Pharma has made since the drop from 97-cents. It's diversified drug pipeline had been cash cow as management has been resourceful in making Elite more self-sufficient. Imo, NDA filing is close at hand. I doubt ELTP regresses back to the 20s.
Cheers!
You mean the Profits and Drugs of Elite would drive the next upward swing to dollar land. There is no denying what the upcoming financials and CC would suggest as guidance for 2016.
Cheers!
Your bud might know something about Elite. The next run will not be fueled by hot air.
Cheers!
Depending on the circumstances, it could be a good thing or bad thing for companies not generating positive cash flows. In Elite's previous financial reporting, an increase in revenues and a net income growth are signs in which the company is headed towards self-sufficiency. It sure reinforces my belief that the fear of a RS is a welcoming strategy of Elite continues to make more record breaking revenues.
Cheers!
Elite Pharmaceuticals, Inc. to Host Conference Call and Webcast to Discuss 2nd Quarter 2016 Financial Results on November 10, 2015
Financials for 2nd Quarter Ended September 30, 2015 will be released on November 9, 2015
Elite Pharmaceuticals, Inc.
9 minutes ago
GlobeNewswire
Northvale, NJ, Nov. 05, 2015 (GLOBE NEWSWIRE) --
Cheers!
Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, announced today that its second quarter financial results will be released on Monday, November 9, 2015. Following the announcement, Elite's management will host a live conference call and webcast on Tuesday, November 10th at 11:00 a.m. EST to review the company's financial and operating results and provide a general business update. Company executives will conduct a question and answer session following their remarks.
Interested parties may listen to the call via a live audio webcast which may be accessed by visiting the investor relations section of Elite's website. Please connect to the website a few minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast.
Conference Call Information
Date: Tuesday, November 10, 2015
Time: 11:00 a.m. EST
Webcast (live and archive) & Audio Replay: http://ir.elitepharma.com/events_presentations
Dial-in numbers: 1-800-346-7359 (domestic)
1-973-528-0008 (international)
Conference number: 98840
Get ready for the ONE-TWO punch that would be lights out for Elite's critics. The reminder would serve to keep shareholders busy on their toes, and what might be expected in 2016.
Cheers!
Share price is being tested, including investors' will and nerves.
Cheers!
Would love to see ELTP gradually move upward with less drama as we see the critics fall off through attrition. Elite is not your typical OTC company. Looks like we found something special here.
Cheers!
You have just described 100% of the stocks that are trading in the market. The more "flippers" ELTP attracts, then the higher she goes. If ELTP goes high enough, then comes the MM and institutions, and off to $2-$5 for starters.
Cheers!
What is wrong with investors that flip shares? They have their role in moving ELTP to higher ground.
Cheers!